Social Security Fund Balance Reaches 10.8 Trillion Yuan as Patient Capital Doubles Down on AI and Electronics

Social Security Fund Runs Smoothly, Cumulative Balance Exceeds 10.8 Trillion Yuan

The Ministry of Human Resources and Social Security released the national social insurance fund performance data for Q1 2025 at a recent routine press conference. The figures show that as of the end of March, total revenue from the three major social insurance funds reached 2.54 trillion yuan, with total expenditures of 2.06 trillion yuan. The cumulative balance surpassed 10.8 trillion yuan, indicating overall stable fund operations.

This massive pool of capital is deeply engaging in the capital markets with the posture of "patient capital," with its core philosophy of long-term and value investing continuously evident in the market positioning of pension insurance funds.

Pension Funds Appear in Over 100 Listed Companies, Electronics Sector a Key Focus

According to Securities Times, as of April 28, pension fund accounts have appeared on the top-ten tradable shareholder lists of over 100 listed companies. In terms of investment allocation, electronics, pharmaceutical and biotech, and basic chemicals have emerged as the three key sectors where pension funds are increasing their positions.

The heavy weighting of the "electronics" sector is particularly noteworthy. Amid the current global AI industry wave, the electronics sector encompasses core segments of the AI supply chain, including semiconductor chips, consumer electronics, and optical and optoelectronic components. The pension funds' continued increase in this sector is widely interpreted by the market as a firm vote of confidence in the long-term growth potential of China's AI hardware supply chain.

In terms of specific areas, sub-sectors such as AI chips, advanced packaging, and high-end memory are at a critical juncture of domestic substitution and technological upgrading. The entry of patient capital not only provides stable financial support for related companies but also sends an important signal of long-term optimism for the industry.

A 'Two-Way Embrace' Between Patient Capital and the AI Industry

Industry analysts point out that as a typical source of long-term funding, social security funds have an investment logic that is highly aligned with the development rhythm of the AI industry. AI technology often requires a lengthy incubation period from fundamental R&D to commercial deployment, and patient capital possesses precisely the ability to ride through cyclical fluctuations, offering sustained support during the early and growth stages of industrial development.

Currently, China's AI industry is undergoing a critical transformation from "model capability breakthroughs" to "large-scale industrial applications." The rapid rise of domestic large language models, represented by DeepSeek, has driven robust demand across the upstream electronics supply chain, including computing chips, servers, and data centers. In the pharmaceutical and biotech space, AI-driven drug discovery and intelligent diagnostics are also demonstrating enormous application potential — all of which align with the pension funds' heavily weighted sectors.

Furthermore, at the national level, authorities have repeatedly emphasized the need to "strengthen patient capital" and guide long-term funds into the market in recent years. The proactive positioning of social security funds in AI-related sectors is a concrete manifestation of the convergence between policy direction and market trends.

Outlook: Long-Term Capital Expected to Continue Adding Core Tech Assets

Looking ahead, as AI technology accelerates its penetration across industries, the electronics sector — serving as the "hardware foundation" of the AI industry — is expected to continue attracting patient capital. Analysts anticipate that backed by the 10.8-trillion-yuan balance, the proportion of market-oriented investment by social security funds still has room to grow. Cross-cutting areas such as AI chips, intelligent terminals, and AI-plus-pharmaceuticals may become key allocation targets in the next phase.

For AI technology companies, the sustained inflow of patient capital means more stable valuation support and a more favorable development environment. This "two-way embrace" between long-term capital and cutting-edge technology is injecting lasting momentum into the high-quality development of China's AI industry.